News und Analysen
LivaNova Announces Publication Detailing the Design of the RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a publication in Contemporary Clinical Trials1, which details the design for “A Prospective
LivaNova to Host Conference Call for Second Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second quarter 2020 results on Wednesday, July 29, 2020 at 12 p.m
AstraZeneca: Kurs-Irrsinn nach Impfstoff-News
Papiere des britischen Pharmakonzerns AstraZeneca (WKN: 886455) verteuern sich heute Morgen um zeitweise +30% auf 120 Euro. Börsenlaien lassen sich von einem am Wochenende vermeldeten Impfstoff-Deal
LivaNova Announces Pricing of Private Offering of $250 Million of 3.00% Cash Exchangeable Senior Notes Due 2025
LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) today announced the pricing of $250 million aggregate principal amount of 3.00% cash exchangeable senior notes due 2025 to be issued by its wholly owned U.S
LivaNova Announces New Senior Secured Credit Facility
LivaNova PLC (NASDAQ:LIVN) (“The Company” or “LivaNova”) today announced its entry into a five-year $450 million senior secured credit facility (the “Credit Facility”) through its wholly owned U.S
LivaNova Announces Proposed Private Offering of $250 Million of Cash Exchangeable Senior Notes
LivaNova PLC (NASDAQ:LIVN) ("LivaNova") today announced its intention to offer $250 million aggregate principal amount of cash exchangeable senior notes due 2025 through its wholly owned U.S
LivaNova to Present at the Jefferies Virtual Healthcare Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Thad Huston, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference on
New Data on LivaNova Perceval Sutureless Aortic Valve Show Consistent Outcomes, Lower Procedure Times Compared to Sutured Valves
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, presented the first data from the Perceval® Sutureless Implant Versus Standard-Aortic Valve Replacement
New Study Shows Significant Positive Impact of Vagus Nerve Stimulation Therapy for Patients with Treatment-Resistant Bipolar Depression
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the publication of a new study in the International Journal of Bipolar Disorders1 that showed
LivaNova to Present PERSIST-AVR Findings at American Association for Thoracic Surgery 100th Annual Meeting
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will present new findings from its Perceval® Sutureless Implant Versus Standard-Aortic Valve Replacement
LivaNova to Present at the UBS Virtual Global Healthcare Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald, Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference on
Clinigen: IL-2 Plays Role in Emerging TIL Therapies
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company acknowledges the presentation of results from the Phase I trial “Durable complete responses
LivaNova Reports First Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2020.
For the first quarter of 2020, worldwide sales
LivaNova Bi-Flow-Kanüle erhält CE-Zeichen für ECMO-Anwendungen
LivaNova PLC (NASDAQ:LIVN), ein marktführendes Unternehmen für Medizintechnik und Innovationen, gab heute bekannt, dass seine Bi-Flow-Kanüle für extrakorporale Membranoxygenierung (ECMO) die
LivaNova Bi-Flow Cannula Receives CE Mark for ECMO Applications
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned CE Mark approval for
GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1)
LivaNova Permitted to Modify Cardiopulmonary Products' Indications for Use to Include ECMO Therapy Beyond Six Hours to Address COVID-19
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that several of its cardiopulmonary products are now permitted to be used in the U.S. for
LivaNova to Host Conference Call for First Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2020 results on Wednesday, April 29, 2020 at 1 p.m
LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at American College of Cardiology and World Congress of Cardiology Virtual Meeting
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced two abstracts focused on implantable neuromodulation technology for patients with heart
Symmetry, das LivaNova VNS Therapy-System für schwer zu behandelnde Depressionen, erhält CE-Prüfzeichen
LivaNova PLC (NASDAQ:LIVN), ein marktführendes medizintechnisches Innovationsunternehmen, gab heute bekannt, dass sein System Vagus Nerve Stimulation Therapy® (VNS Therapy) Symmetry™ die
LivaNova VNS Therapy System, Symmetry, Granted CE Mark for Difficult-to-Treat Depression
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Vagus Nerve Stimulation Therapy® (VNS Therapy) System, Symmetry™, earned CE Mark approval
LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depression
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a research collaboration with Verily, an Alphabet company, to capture measures of depression
LivaNova Reports Fourth Quarter and Full-Year 2019 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2019.
For the fourth quarter of
LivaNova Receives FDA Clearance for 3T Heater-Cooler Device Modification
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for a device
New International Consensus Statement Proposes “Difficult-to-treat Depression” as a More Clinically Useful Definition than “Treatment-Resistant Depression”
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, commends the recent international consensus statement published in the Journal of Affective Disorders for